未名医药：重要子公司被暂停生产 若三个月内无法恢复生产公司可能触发其他风险警示

Core Viewpoint - The company, Weiming Pharmaceutical, faces significant operational challenges due to the suspension of production and sales at its key subsidiary, Tianjin Weiming, which may lead to further risk warnings if production is not resumed within three months [1] Group 1: Company Impact - Tianjin Weiming, a major subsidiary, was ordered to suspend production and sales by the Tianjin Municipal Drug Administration on April 22, 2025 [1] - In 2024, Tianjin Weiming generated revenue of 217 million yuan and reported a net loss of 14.0037 million yuan, accounting for 60.09% of the company's total revenue and 9.8% of the consolidated net profit [1] - The suspension of operations is expected to have a significant impact on the company's overall business performance [1] Group 2: Risk Factors - If Tianjin Weiming is unable to resume production within three months, the company may trigger additional risk warnings [1]